Washington wants the population to be given even more of the controversial gene injections in the fall. As a result, the US government ordered 105 million more vaccine doses from Pfizer – with an option for an additional 195 million. The price: a whopping $3.2 billion.
If the US government has its way, people in the United States should get more of the experimental and controversial mRNA vaccines (also known as “gene therapies”) this fall. That’s why there’s a new billion-dollar deal with Pfizer. Accordingly, 105 million doses of Corminaty have already been ordered and an additional option of 195 million doses is included. According to media reports, this is a $3.2 billion deal for the pharmaceutical companywhich since the first quarter of 2021 record sales and, after a few difficult years, is also making very high profits.
Pfizer boss Bourla described the controversial mRNA vaccine, which is based on the original Wuhan variant, as a protective measure that is also intended to protect against the mutated variants – not to forget that a lawsuit against Pfizer/BioNTech is pending. “As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that can protect against current and future variants,” said Albert Bourla, Pfizer’s chairman and chief executive officer, although study data for speak the opposite. “Vaccines are and will remain critical to protecting people of all ages from Covid-19. We remain proud of our longstanding partnership with the U.S. government in fighting this pandemic and the continued impact of immunization efforts in the United States and around the world.”
“This agreement will provide additional doses for US residents and help manage the next wave of Covid-19. Pending regulatory approval, it will also include an Omicron-adapted vaccine, which we believe is important to combat the rapidly spreading Omicron variant,” said Sean Marett, BioNTech’s chief business and chief commercial officer. “We appreciate the continued partnership with the US government in our common goal of ending this pandemic.” But given the already extremely poor performance of these mRNA syringes, the question arises as to whether the harm-benefit ratio of these “adapted” vaccines will actually be better.
In any case, the Pfizer shareholders in particular will be happy about the deal, which once again throws fresh taxpayer money down the insatiable throat of the pharmaceutical company. So the “vaccination subscription” definitely pays off for the company, especially since Europeans and other countries also order vast quantities of Pfizer’s mRNA shots.
